Lv1
40 积分 2026-06-08 加入
不同分子分型乳腺癌患者临床病理特征及预后因素分析
2天前
已完结
Prediction of survival after de-escalated neoadjuvant therapy in HER2-positive early breast cancer: a pooled analysis of three WSG trials
8天前
已完结
Ditsch N,et al.Breast Care (Basel) . 2020 Jun;15(3)294-309
8天前
已完结
Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials
9天前
已完结
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
12天前
已完结
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer
12天前
已完结
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer
1个月前
已完结
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
皖公网安备34019202002308
